2-(2-vinylphenyl)benzyl chloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-vinylphenyl)benzyl chloride
• 英文别名: 1-(Chloromethyl)-2-(2-ethenylphenyl)benzene
• 化学式: C₁₅H₁₃Cl
• 分子量: 228.721
• InChiKey: KPKDKKMLYDMMRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  tert-butyl ({3-[amino(oxo)acetyl]-2-methyl-1H-indol-4-yl}oxy)acetate 、 2-(2-vinylphenyl)benzyl chloride 在 sodium hydride 、 水 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.5h， 生成 Tert-butyl 2-[1-[[2-(2-ethenylphenyl)phenyl]methyl]-2-methyl-3-oxamoylindol-4-yl]oxyacetate
  参考文献：
  名称：

  WO2007/56279

  摘要：

  公开号：

文献信息

• Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
  申请人：Chang Han-Ting

  公开号：US20070135383A1

  公开（公告）日：2007-06-14

  The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.

  本发明提供了治疗磷脂酶相关疾病的方法和组合物。具体地，本发明提供了一种用于治疗动物主体中的胰岛素相关、体重相关和/或胆固醇相关疾病的方法。该方法通常涉及在胃肠道腔中定位的非吸收和/或外流的磷脂酶A2抑制剂的给药。
• PHOSPHOLIPASE INHIBITORS LOCALIZED IN THE GASTROINTESTINAL LUMEN
  申请人：Ilypsa, Inc.

  公开号：EP1747003A1

  公开（公告）日：2007-01-31
• EP1747003A4
  申请人：——

  公开号：EP1747003A4

  公开（公告）日：2008-01-09
• PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS
  申请人：Ilypsa, Inc.

  公开号：EP1951315A2

  公开（公告）日：2008-08-06
• Phospholipase Inhibitors Localized in the Gastrointestinal Lumen
  申请人：Charmot Dominique

  公开号：US20070292385A1

  公开（公告）日：2007-12-20

  The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.